



ARMED WITH PROPEL

# Complete your in-office arsenal with PROPEL

## PROPEL FITS WITHIN YOUR IN-OFFICE PRACTICE

Improve sinus surgery outcomes for your patients with chronic rhinosinusitis (CRS) by offering PROPEL implants in your in-office practice through a two-pronged approach: in-office sinus procedures or postoperatively.



**PROPEL  
IN-OFFICE  
IMPLANT  
OPTIONS**

- 1 IN-OFFICE SINUS PROCEDURES**  
Implants following in-office ESS such as balloon sinus dilation
- 2 POSTOPERATIVE UTILIZATION**  
Implants during the postoperative healing period after sinus surgery

### CLINICAL APPLICATION

- + Intended for use following sinus surgery to maintain patency, thereby reducing the need for postoperative surgical intervention and use of oral steroids<sup>1-3</sup>
- + Separate mucosal tissues, provide stabilization of the middle turbinate, prevent obstruction by adhesions, and reduce edema/inflammation<sup>1-3</sup>
- + Innovative 2-in-1 technology that opens the sinuses while delivering mometasone furoate directly where it is needed<sup>1-3</sup>

### COVERAGE

- + Positive coverage and access with commercial payors, such as UnitedHealthCare, Blue Cross Blue Shield FEP, and HCSC\*†
- + Positive coverage and access with government payors, such as VA, TriCare, and select Medicare plans\*†
- + Billing a CPT code for in-office use of PROPEL implants is applicable

### VALUE TO YOUR PRACTICE

- + Easily loaded; fast and precise deployment
- + Innovative technology for your patients with CRS, with tools to facilitate patient outreach
- + Dedicated team to assist with payor coverage and reimbursement
- + Tailored care for your patients with PROPEL implants: Implants of varying sizes and shapes indicated to treat the frontal, maxillary, and ethmoid sinuses<sup>1-3</sup>

Actor portrayal with simulated endoscopy.

CPT, current procedural terminology; ESS, endoscopic sinus surgery; FEP, federal employee program; HSCS, Health Care Service Corporation; VA, Veterans Affairs.

\*Coverage information as of September 2020.

†DISCLAIMER: This is not a guarantee of payment, coverage, or reimbursement. Individual payer plans may vary.

Explore the benefits of PROPEL implants at [PROPELOpens.com](http://PROPELOpens.com)



## Arm yourself with **PROPEL** in the office

### MORE THAN 7,000 PATIENTS TREATED IN THE OFFICE SINCE 2011<sup>4</sup>


Choose from 3 steroid-eluting implants under one brand to select the best option that conforms to the anatomical needs of your patients.

The following information is for processing and payment for sinus implants when used in the non-facility setting:

HCPICS	DESCRIPTION	BILLABLE UNITS	SITE OF SERVICE
J7401	Mometasone furoate sinus implant, 10 micrograms	10 micrograms = 1 unit billed	11 (In-office)

For unilateral placement of a drug-eluting sinus implant, report 37 units (370 mcgs/10 = 37 units)

For bilateral placement of a drug-eluting sinus implant, report 74 units (370 mcgs x 2 = 740/10 = 74 units)



#### ETHMOID SINUS

**PROPEL MINI** (NDC: 10599-0001-01)  
**PROPEL** (NDC: 10599-0000-01)

#### FRONTAL SINUS OSTIA

**PROPEL MINI** (NDC: 10599-0001-01)  
**PROPEL CONTOUR** (NDC: 10599-0002-01)

#### MAXILLARY SINUS OSTIA

**PROPEL CONTOUR** (NDC: 10599-0002-01)

Learn more at [PROPELOpens.com](http://PROPELOpens.com)

**PROPEL implants were evaluated in clinical trials that included patients with and without nasal polyps, undergoing primary or revision surgery by traditional instrumentation or ballooning procedures<sup>5</sup>**

### YOUR PATIENTS + PROPEL = IMPROVED OUTCOMES

The PROPEL sinus implants are indicated to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age after sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with intolerance to mometasone furoate (MF) or hypersensitivity

to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at [www.IntersectENT.com/technologies/](http://www.IntersectENT.com/technologies/). Rx only.

**References:** **1.** PROPEL [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2013. **2.** PROPEL Mini [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016. **3.** PROPEL Contour [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016. **4.** Data on file. Intersect ENT, Inc. Through Q3 2020. **5.** Han JK, et al. *Int Forum Allergy Rhinol.* 2012;2(4):271-279.